Myasthenia Gravis Treatment Market by Medication (Cholinesterase Inhibitors, Corticosteroids, Immunosuppressants, Plasmapheresis, Intravenous immunoglobulin (IVIg), Monoclonal Antibody), by Distribution channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027

  • To Be Published : Jul 2019 |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Myasthenia gravis (MG) is a type of chronic autoimmune neuromuscular disease which causes weakness in skeletal muscles in the arms and legs. Double vision, facial paralysis, difficulty in walking, dropping of eyelids, are symptoms of myasthenia gravis. This disease is diagnosed by tests such as repetitive nerve stimulation test, blood test for antibodies, edrophonium test, Computed Tomography (CT), and Magnetic Resonance Imaging (MRI). Corticosteroids drugs (azathioprine, and cyclosporine) and Acetylcholine esterase inhibitors (Edrophonium, and Pyridostigmine) are used for the treatment of MG.

Myasthenia Gravis Treatment Market Drivers

Consistent research and development activities are expected to propel growth of the myasthenia gravis treatment market. For instance, in October 2017, Alexion Pharmaceuticals, Inc. received approval from the U.S. Food and Drug Administration for Soliris which contains eculizumab as an active component. This drug is used for treatment of antibody positive generalized myasthenia gravis, and it is also used in treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS).

Furthermore, increasing number of clinical trials for treatment of myasthenia gravis are expected to drive the myasthenia gravis treatment market growth. For instance, in December 2017, Novartis AG initiated phase II clinical trial of CFZ533 for treatment of severe myasthenia gravis. The main function of CFZ533 is the modification of immune response by deactivation of white blood cells. Hence, it is expected to help with improvement and management of severe myasthenia gravis.

Moreover, Argenx BVBA is conducting a clinical phase III study of ARGX-113 for treatment of generalized myasthenia gravis. ARGX-113, also named Efgartigimod, is administered intravenously. The study started in March 2019 and is expected to complete in June 2021.

 Myasthenia Gravis Treatment Market Restraints

Side effects of the drugs used for treating myasthenia gravis are expected to hamper growth of the myasthenia gravis treatment market. For instance, according to BioNews Services, LLC report, in April 2019, high dose combination of cholinesterase inhibitors (ChEIs) and calcineurine inhibitors (CNIs) such as Mestinon and Prograf are responsible for severe muscle cramps in myasthenia gravis patients. Hence, this factor is expected to hinder growth of the myasthenia gravis treatment market.

Myasthenia Gravis Treatment Market- Regional Analysis

On the basis of region, the global myasthenia gravis treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to hold a dominant position in the myasthenia gravis treatment market over the forecast period. This is owing to increasing incidence and prevalence of myasthenia gravis in the U.S. For instance, in October 2018, according to the National Center for Biotechnology Information (NCBI), incidence of myasthenia gravis was around 5 to 30 cases per million person years and prevalence is around 10 to 20 cases per 100,000 population in U.S.

Furthermore, Asia Pacific is projected to witness significant growth in the global myasthenia gravis treatment market, owing to increasing research and development activities for treatment of myasthenia gravis. For instance, Sun Yat-Sen University in China is conducting phase III clinical trial of Azathioprine and Leflunomide for treatment of myasthenia gravis. The study started in September 2012, and is expected to complete in January 2020.

Key players operating in the myasthenia gravis treatment market are Novartis AG, Takeda Pharmaceutical Company Limited, Grifols, S.A., Valeant Pharmaceutical International, Inc. Alexion Pharmaceutical Inc., F. Hoffmann-La Roche AG, CSL Behring, Baxter International, Inc., Shire plc, and Avadel Pharmaceutical, PLC.

Myasthenia Gravis Treatment Market –Taxonomy

By Medications

  • Cholinesterase Inhibitors
  • Corticosteroids
  • Immunosuppressants
  • Plasmapheresis
  • Intravenous immunoglobulin (IVIg)
  • Monoclonal Antibody

By Distribution Channels

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.

Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.
Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.